SciELO - Scientific Electronic Library Online

 
vol.36 issue6Delphi consensus on the diagnosis and management of dyslipidaemia in chronic kidney disease patients: A post hoc analysis of the DIANA studyThe relationship between dietary salt intake and ambulatory blood pressure variability in non-diabetic hypertensive patients author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Nefrología (Madrid)

On-line version ISSN 1989-2284Print version ISSN 0211-6995

Abstract

DRAIBE, Juliana; PEPPER, Ruth J.  and  SALAMA, Alan D.. Treatment with Quinoline-3-carboxamide does not successfully prevent immune-mediated glomerulonephritis in mice. Nefrología (Madr.) [online]. 2016, vol.36, n.6, pp.687-693. ISSN 1989-2284.  https://dx.doi.org/10.1016/j.nefro.2016.03.012.

Introduction:

Quinoline-3-carboximide compounds, such as paquinimod, which targets the protein S100A9, have demonstrated efficacy in treating autoimmune diseases. S100A9, in association with S100A8, forms the heterodimer S100A8/S100A9, known as calprotectin; that has been shown to be upregulated in numerous inflammatory disorders. We had previously demonstrated protection from glomerular disease in S100A9-deficient mice. The aim of this study was to assess the efficacy of paquinimod in the prevention and treatment of experimental glomerulonephritis.

Methods:

Nephrotoxic nephritis (NTN) was induced in C57BL/6 mice according to our standard protocol. Mice were treated with different doses of paquinimod either at disease induction (prevention group) or two days following induction (therapeutic group) and sacrificed 8 days following induction. Disease was assessed histologically (number of glomerular crescents, degree of glomerular thrombosis, number of infiltrating leucocytes and calprotectin expression) and biochemically (serum creatinine and urea levels, and urinary levels of protein).

Results:

Neither treatment with low (0.5 mg/kg) or high (25 mg/kg) doses of paquinimod, given preventatively or therapeutically, led to disease attenuation, as assessed by biochemical or histological parameters. Additionally, we found trends for an increase in renal glomerular calprotectin expression in the high dose groups, suggesting a possible feedback regulation of calprotectin expression.

Conclusions:

Our results show that paquinimod does not successfully prevent or treat mice with NTN. Other models of immune-mediated glomerulonephritis need to be tested to investigate the therapeutic potential of this compound in renal disease.

Keywords : Glomerulonephritis; Animal model; Calprotectin; Paquinimod.

        · abstract in Spanish     · text in English     · English ( pdf )